Acorda Therapeutics Inc (ACOR)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

420 SAW MILL RIVER ROAD ARDSLEY, NY 10502

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III clinical trial for the improvement of walking ability in people with multiple sclerosis. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations.

Data as of 2020-09-12
Market Cap21.591 Million Shares Outstanding47.979 Million Avg 30-day Volume1.762 Million
P/E Ratio Dividend Yield EPS-4.68
Price/Sales0.135 Price cash flow ratio7.4 Price free cash flow ratio-0.2
Book Value6.06 Price to Tangible Book-0.25 Alpha-0.06
Short Interest Ratio % Short Interest to Float R-squared0.116865
BETA1.46113 52-week High/Low4.08 / 0.4335 Stddev0.182623
View SEC Filings from ACOR instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 82 108 -24.07% 29 (1.89%) 29 (1.85%) 0.0%
13F shares: 23.978 Million 42.736 Million -43.89% 13.98 Million 14.813 Million -5.62%
% Ownership 49.9744 89.0394 -43.87% 29.1367 30.8616 -5.59%
New Positions: 18 11 63.64% 7 4 75.0%
Increased Positions 14 34 -58.82% 7 6 16.67%
Closed Positions 43 26 65.38% 7 10 -30.0%
Reduced Positions 28 38 -26.32% 7 14 -50.0%
Total Calls 109.223 Thousand 111.066 Thousand -1.66% 37 Thousand 30.9 Thousand 19.74%
Total Puts 3.257 Million 3.513 Million -7.29% 1.958 Million 1.944 Million 0.7%
PUT/CALL Ratio 29.82 31.63 -5.72% 52.91 62.92 -15.91%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ACOR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACOR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PANEM SANDRA PHD

  • Director
0 2020-06-15 1

JENSEN PEDER

  • Director
0 2020-06-15 1

KELLEY JOHN P

  • Director
0 2020-06-15 1

GREENE BARRY E

  • Director
0 2020-06-15 1

RAUSCHER STEVEN M

  • Director
0 2020-06-15 1

RANDALL LORIN

  • Director
0 2020-06-15 1

STRADER CATHERINE D.

  • Director
0 2020-06-15 1

LAWRENCE DAVID CHIEF, BUS. OPS & PAO

  • Officer
12,961 2019-12-02 2

COHEN RON PRESIDENT AND CEO

  • Officer
  • Director
632,437 2019-12-02 2

WASMAN JANE PRESIDENT, INTL AND GC

  • Officer
117,420 2019-12-02 2

SABELLA LAUREN M CHIEF COMMERCIAL OFFICER

  • Officer
12,624 2019-12-02 2

BLANK BURKHARD CMO AND HEAD OF R&D

  • Officer
0 2019-11-07 1

HINDMAN ANDREW A. CHIEF BUSINESS OFFICER

  • Officer
15,639 2019-03-08 0

SCOPIA CAPITAL MANAGEMENT LP

SCOPIA MANAGEMENT, INC.

SIROVICH MATTHEW

MINDICH JEREMY

  • 10% Owner
4,750,219 2019-01-30 0

SMITH IAN F

  • Director
0 2018-06-27 0

BATYCKY RICHARD P. CHIEF TECH. OFF. & SITE HEAD

  • Officer
55,513 2018-02-22 0

BLIGHT ANDREW CHIEF SCIENTIFIC OFFICER

  • Officer
78,594 2017-03-01 0

ROGERS MICHAEL W CHIEF FINANCIAL OFFICER

  • Officer
0 2016-05-11 0

CARRAZANA ENRIQUE J. CHIEF MEDICAL OFFICER

  • Officer
32,148 2015-12-01 0

WESSEL THOMAS CHIEF MEDICAL OFFICER

  • Officer
36,350 2011-03-03 0

YOUNG WISE

  • Director
17,307 2010-06-09 0

PHILLIPS BARCLAY A

  • Director
308,801 2008-06-13 0

RIDGEBACK CAPITAL INVESTMENTS LTD.

RIDGEBACK CAPITAL MANAGEMENT LLC

HOLMAN WAYNE GEORGE

  • 10% Owner
No longer subject to file 2008-01-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments